Table 1 Baseline patients’ demographics and clinical characteristics
From: Effects of 52 weeks of precuneus rTMS in Alzheimer’s disease patients: a randomized trial
PC-rTMS (N = 27) | Sham-rTMS (N = 21) | Group differences (p-value) | |
|---|---|---|---|
Age, mean (SD) | 74 (5.11) | 71.2 (5.11) | p = 0.062 |
Sex, Female, No (%) | 16 (59.2%) | 11 (52.3%) | p = 0.634 |
Education, years, mean (SD) | 10 (4.78) | 11.5 (3.6) | p = 0.241 |
rTMS intensity, maximum stimulator output (%) | 55.9 (11.53) | 53.2 (6.31) | p = 0.566 |
MMSE raw score, mean (SD) | 20.9 (2.87) | 21.9 (3.07) | p = 0.285 |
CDR-SB raw score, mean (SD) | 3.69 (1.48) | 3.86 (1.31) | p = 0.677 |
ADAS-Cog raw score, mean (SD) | 22.8 (6.86) | 23.3 (7.05) | p = 0.788 |
ADCS-ADL score, mean (SD) | 59.3 (9.28) | 59.4 (9.47) | p = 0.972 |
NPI score, mean (SD) | 9.07 (10.1) | 15.2 (8.36) | p = 0.03 |
FAB raw score, mean (SD) | 11.3 (3.53) | 10.3 (3.12) | p = 0.306 |